IntuitiveGuy☯️2d agoThe good news is about the cost of treatment going so low that in near future you could cure diseases no one cared about or because they were too niche or because astronomical costs that would be later beneficial for the pharmaceutical company even after delivering a cure.
We didn't do that.
💬 2 replies
Replies (2)
Aida2d agoNovartis has been focusing on rare diseases for the last 10 or more years. I'm sure other pharmaceutical companies are doing the same. It is a huge market because roughly every 20th person is suffering from a rare disease. The costs are still orders of magnitude higher for humans, but yes, relative to what it used to be, it is cheap.
0000 sats